These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 30559738)

  • 21. PD-L1-expressing dendritic cells contribute to viral resistance during acute HSV-1 infection.
    Bryant-Hudson KM; Carr DJ
    Clin Dev Immunol; 2012; 2012():924619. PubMed ID: 22474484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice.
    Dimitrov V; Bouttier M; Boukhaled G; Salehi-Tabar R; Avramescu RG; Memari B; Hasaj B; Lukacs GL; Krawczyk CM; White JH
    J Biol Chem; 2017 Dec; 292(50):20657-20668. PubMed ID: 29061851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity.
    Karunarathne DS; Horne-Debets JM; Huang JX; Faleiro R; Leow CY; Amante F; Watkins TS; Miles JJ; Dwyer PJ; Stacey KJ; Yarski M; Poh CM; Lee JS; Cooper MA; Rénia L; Richard D; McCarthy JS; Sharpe AH; Wykes MN
    Immunity; 2016 Aug; 45(2):333-45. PubMed ID: 27533014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.
    Fu Y; Liu CJ; Kobayashi DK; Johanns TM; Bowman-Kirigin JA; Schaettler MO; Mao DD; Bender D; Kelley DG; Uppaluri R; Bi WL; Dunn IF; Tao Y; Luo J; Kim AH; Dunn GP
    Sci Rep; 2020 Jun; 10(1):9027. PubMed ID: 32493985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.
    Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.
    Hobo W; Maas F; Adisty N; de Witte T; Schaap N; van der Voort R; Dolstra H
    Blood; 2010 Nov; 116(22):4501-11. PubMed ID: 20682852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
    Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
    Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment.
    Takehara T; Wakamatsu E; Machiyama H; Nishi W; Emoto K; Azuma M; Soejima K; Fukunaga K; Yokosuka T
    Commun Biol; 2021 May; 4(1):581. PubMed ID: 33990697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
    Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
    Front Immunol; 2020; 11():596825. PubMed ID: 33424844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy.
    Xu Y; Gao Z; Hu R; Wang Y; Wang Y; Su Z; Zhang X; Yang J; Mei M; Ren Y; Li M; Zhou X
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34697216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
    Horlad H; Ma C; Yano H; Pan C; Ohnishi K; Fujiwara Y; Endo S; Kikukawa Y; Okuno Y; Matsuoka M; Takeya M; Komohara Y
    Cancer Sci; 2016 Nov; 107(11):1696-1704. PubMed ID: 27564404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tissue expression of PD-L1 mediates peripheral T cell tolerance.
    Keir ME; Liang SC; Guleria I; Latchman YE; Qipo A; Albacker LA; Koulmanda M; Freeman GJ; Sayegh MH; Sharpe AH
    J Exp Med; 2006 Apr; 203(4):883-95. PubMed ID: 16606670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
    Song MY; Park SH; Nam HJ; Choi DH; Sung YC
    J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation.
    Kuipers H; Muskens F; Willart M; Hijdra D; van Assema FB; Coyle AJ; Hoogsteden HC; Lambrecht BN
    Eur J Immunol; 2006 Sep; 36(9):2472-82. PubMed ID: 16917960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uncovering the mysteries of hantavirus infections.
    Vaheri A; Strandin T; Hepojoki J; Sironen T; Henttonen H; Mäkelä S; Mustonen J
    Nat Rev Microbiol; 2013 Aug; 11(8):539-50. PubMed ID: 24020072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8
    Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T
    J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
    Takada K; Toyokawa G; Kinoshita F; Jogo T; Kohashi K; Wakasu S; Ono Y; Tanaka K; Oba T; Osoegawa A; Tagawa T; Azuma K; Okamoto I; Shimokawa M; Oda Y; Mori M
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2639-2650. PubMed ID: 32405745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Involvement of Programmed Cell Death Ligands in Skin Immune Responses.
    Tanaka R; Ichimura Y; Kubota N; Saito A; Nakamura Y; Ishitsuka Y; Watanabe R; Fujisawa Y; Mizuno S; Takahashi S; Fujimoto M; Okiyama N
    J Invest Dermatol; 2022 Jan; 142(1):145-154.e8. PubMed ID: 34310947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2.
    Li Y; Liang Z; Tian Y; Cai W; Weng Z; Chen L; Zhang H; Bao Y; Zheng H; Zeng S; Bei C; Li Y
    Cancer Sci; 2018 Aug; 109(8):2435-2445. PubMed ID: 29890018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
    Liu J; Li H; Sun L; Yuan Y; Xing C
    Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.